BioAtla, Inc.
BCAB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $11 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $1 | $1 | $1 | $0 |
| Gross Profit | $10 | -$1 | -$1 | $0 |
| % Margin | 91.6% | – | – | 100% |
| R&D Expenses | $63 | $104 | $79 | $58 |
| G&A Expenses | $22 | $26 | $29 | $38 |
| SG&A Expenses | $22 | $26 | $29 | $38 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1 | -$1 | -$1 | $0 |
| Operating Expenses | $84 | $128 | $107 | $97 |
| Operating Income | -$74 | -$130 | -$108 | -$96 |
| % Margin | -672.2% | – | – | -38,576% |
| Other Income/Exp. Net | $4 | $6 | $2 | $1 |
| Pre-Tax Income | -$70 | -$123 | -$106 | -$95 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$70 | -$123 | -$105 | -$95 |
| % Margin | -634.3% | – | – | -38,160.8% |
| EPS | -1.44 | -2.58 | -2.74 | -2.76 |
| % Growth | 44.2% | 5.8% | 0.7% | – |
| EPS Diluted | -1.44 | -2.58 | -2.74 | -2.76 |
| Weighted Avg Shares Out | 49 | 48 | 39 | 35 |
| Weighted Avg Shares Out Dil | 49 | 48 | 39 | 35 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $6 | $2 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$73 | -$122 | -$105 | -$94 |
| % Margin | -663.8% | – | – | -37,627.6% |